Last reviewed · How we verify
double dose Morphine
Morphine acts as a mu-opioid receptor agonist, producing analgesia by activating these receptors in the brain and spinal cord.
Morphine acts as a mu-opioid receptor agonist, producing analgesia by activating these receptors in the brain and spinal cord. Used for Pain management in patients with cancer, Pain management in patients with acute injuries or postoperative pain.
At a glance
| Generic name | double dose Morphine |
|---|---|
| Sponsor | Norwegian University of Science and Technology |
| Drug class | opioid |
| Target | mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
Morphine's analgesic effects are primarily mediated through its binding to mu-opioid receptors, which are G protein-coupled receptors that inhibit the release of pain-producing neurotransmitters. This results in a decrease in the perception of pain. Additionally, morphine can also produce respiratory depression and euphoria through its action on these receptors.
Approved indications
- Pain management in patients with cancer
- Pain management in patients with acute injuries or postoperative pain
Common side effects
- Nausea
- Vomiting
- Constipation
- Dizziness
- Respiratory depression
Key clinical trials
- Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative Pain (PHASE2)
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery (PHASE2)
- PRO-RSTAP: Effect of TAP and RS Blocks on Recovery After Inguinal Hernia Surgery (PRO-RSTAP) (NA)
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (PHASE3)
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) (PHASE3)
- Anrikefon-based Patient-controlled Intravenous Analgesia After Laparoscopic Surgery (PHASE4)
- Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- double dose Morphine CI brief — competitive landscape report
- double dose Morphine updates RSS · CI watch RSS
- Norwegian University of Science and Technology portfolio CI